The negotiations that followed went extraordinarily smoothly. Before long, both sides finalized the details and signed a formal contract.
The Sanqing Anti-Cancer Drug was officially included in Category B of the national medical insurance drug list, becoming the first broad-spectrum anti-cancer drug to be covered by medical insurance.
From then on, cancer patients across the country could take this anti-cancer drug under a doctor's guidance, with treatment plans tailored to their condition.
In general, after taking it for one to three months, cancer could be completely cured regardless of whether it was early-stage or late-stage. As for recurrence afterward, that was another matter.
For a cancer patient, excluding treatment costs, examination fees, hospitalization fees, and other expenses, the medication alone could basically be kept to around 100,000 yuan after medical insurance reimbursement.
For some patients who did not qualify for reimbursement, even paying out of pocket would only cost a little over 200,000 yuan.
A cost of 100,000 yuan was roughly equivalent to one or two years of income for an ordinary working family, already a price most Chinese people could afford.
Even if they had to pay out of pocket, they could still seek reimbursement through commercial insurance.
If a family was truly in financial difficulty, they could borrow from relatives and friends to scrape together the money. They would no longer have to go bankrupt and fall into despair as they had in the past.
For impoverished populations, Sanqing had also joined the Ministry of Civil Affairs' special subsidy program for major disease treatment, providing free anti-cancer drugs every year.
Eligible impoverished farmers, urban and rural minimum-living-standard households, low-income struggling families, key recipients of preferential care, and people in hardship who could not afford treatment for major illnesses could all receive Sanqing's charitable drug donations for the out-of-pocket